Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show, Annual Meeting

Paragonix Presenting Expansive Organ Transplant Research at the International Society of Heart and Lung Transplantation 44th Annual Meeting


Paragonix Technologies, Inc., a pioneer in organ transplant products and services, is honored to announce the forthcoming release of new clinical data supporting the use of controlled hypothermic preservation and clinical services. These presentations compare and analyze post-transplant outcomes of patients, presented by a multi-center panel of clinical investigators representing the GUARDIAN Clinical Registries at the 44th ISHLT Annual Meeting and Scientific Sessions, located at the Prague Congress Center in Prague, Czech Republic from April 10-13, 2024.

Clinical investigators will be sharing data and research related to Paragonix heart and lung devices in five oral presentations and four posters throughout the conference, including:

Additionally, Paragonix will be hosting an Industry Symposium, titled "Reimagined Clinical Standards: Transformative Innovations in Organ Preservation," held at ISHLT on Friday, April 12 at 11:45 PM CET in South Hall 2. The event will feature a panel of three leading thoracic surgeons and investigators of the GUARDIAN Registry as they explore the scientific foundation of advanced organ preservation and examine the associated impact on patient outcomes.

"We're thrilled by the extensive studies being presented at this year's conference that strongly support the development of new and superior organ preservation technologies," said Dr. Lisa Anderson, CEO and President of Paragonix. "It's an honor to have the opportunity to share and celebrate the critical research our esteemed colleagues present each year, as they pave a new way forward and redefine the standard of care in organ transportation."

To visit the Paragonix Technologies exhibit and meet members of their team at ISHLT, visit booth #20. For more information about Paragonix, visit www.paragonix.com.

About Paragonix Technologies

Paragonix Technologies is a leading developer, manufacturer, and service provider in the organ transplant industry, establishing a novel approach to organ preservation.

Paragonix Technologies provides Advanced Organ Preservation ("AOP") devices that safeguard donor organs during the journey between donor and recipient patients. Our FDA-cleared and CE-marked devices incorporate clinically proven and medically trusted cold preservation techniques that allow unprecedented physical and thermal protection to the organ during transit. All Paragonix AOP devices are natively integrated with our novel digital app, delivering real-time organ tracking data and monitoring logistics for transplant teams seeking a secure and centralized solution. For more information, visit www.paragonix.com.

Connect with us on LinkedIn: Paragonix Technologies
Follow us on Twitter: @ParagonixSherpa
Like Us on Facebook: Paragonix SherpaPak

L-594 Ver. 0


These press releases may also interest you

at 08:30
Toitures Hogue's commitment to providing its employees with a structured, professional working environment that guarantees complete safety in the workplace, both on the job and on the job site, has just been awarded its renewed ISO 45001...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

26 avr 2024
ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the...

26 avr 2024
Appili Therapeutics Inc. (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced it has secured additional bridge financing in the amount of C$300,000...

26 avr 2024
David J. Dykeman, co-chair of the Life Sciences & Medical...



News published on and distributed by: